Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

Peter D. Zang,Neal S. Chawla,Regina Barragan-Carrillo,Alex Chehrazi-Raffle,Abhishek Tripathi,Sumanta K. Pal,Tanya B. Dorff

JAMA ONCOLOGY（2024）

引用 0|浏览17

暂无评分

摘要

This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要